Nano-hydroxyapatite radiolabeled with radium dichloride [223Ra] RaCl2 for bone cancer targeted alpha therapy: In vitro assay and radiation effect on the nanostructure
Sara Gemini‐Piperni, Eduardo Ricci‐Júnior, Derya İlem‐Özdemir, Beatriz da Silva Batista, Luciana Magalhães Rebêlo Alencar, Alexandre Malta Rossi, Ralph Santos‐Oliveira
Abstract
The use of targeted alpha therapy (TAT) for bone cancer is increasing each year. Among the alpha radionuclides , radium [ 223 Ra]Ra +2 is the first one approved for bone cancer metastasis therapy. The development of novel radiopharmaceutical based on [ 223 Ra]Ra +2 is essential to continuously increase the arsenal of new TAT drugs . In this study we have developed, characterized, and in vitro evaluated [ 223 Ra] Ra-nano-hydroxyapatite. The results showed that [ 223 Ra] Ra-nano-hydroxyapatite has a dose-response relationship for osteosarcoma cells and a safety profile for human fibroblast cells, corroborating the application as a radiopharmaceutical.